Diego Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
“AI in Target Discovery.
AI integrates multi-omics and network biology to prioritize drug targets and accelerate early validation. Early examples show AI-derived targets reaching clinical trials.
Key gap: biological interpretability and impact on late-stage success remain uncertain.”
Title: Target identification and assessment in the era of AI
Authors: Frank Pun, Dmitriy Podolskiy, Evgeny Izumchenko, Andrew Mortlock, Tudor Oprea, Morten Scheibye-Knudsen, Kristen Fortney, Eric Morgen, Feng Ren, Alex Zhavoronkov
Other articles featuring Diego Díaz García on OncoDaily.
